CLAIMS:

1. Use of an anti-CD3 antibody that comprises an Fc domain having an amino acid modification, wherein said modified Fc domain does not bind any FcγR in the manufacture of a medicament for treating an autoimmune disorder or ameliorating the symptoms thereof in a patient in need thereof, wherein said medicament is to be administered in a therapeutically effective amount to said patient over no more than 11 days wherein said administration comprises a dosage regimen comprising doses of increasing amounts of said antibody on at least the initial 4 days of said dosage regimen; and wherein the dose on day 1 is approximately 1.6 μg/kg, the dose on day 2 is approximately 3.2 μg/kg, the dose on day 3 is approximately 6.5 μg/kg, the dose on day 4 is approximately 13 μg/kg, and the dose on any subsequent days is approximately 26 μg/kg.

2. The use of claim 1, wherein said dosage regimen is 5 days or less.

3. The use of claim 1, wherein said dosage regimen is 6 days or less.

4. The use of claim 1, wherein said dosage regimen is 7 days or less.

5. The use of claim 1, wherein said dosage regimen is 8 days or less.

6. The use of claim 1, wherein said dosage regimen is 9 days or less.

7. The use of claim 1, wherein said dosage regimen is 10 days or less.

8. Use of an anti-CD3 antibody that comprises an Fc domain having an amino acid modification, wherein said modified Fc domain does not bind any FcγR; in the manufacture of a medicament for treating an autoimmune disorder or ameliorating the symptoms thereof in a patient in need thereof, wherein said medicament is to be administered to said patient in a dosage regimen comprising administration of a maximum daily prophylactically or therapeutically effective amount of 35 μg/kg or less of said antibody, over no more than 11 days.

9. The use of claim 8, wherein said maximum daily prophylactically or therapeutically effective amount is 30 μg/kg or less of said antibody.

10. The use of claim 8, wherein said maximum daily prophylactically or therapeutically effective amount is 25 μg/kg or less of said antibody.

11. The use of claim 8, wherein said antibody is a humanized or chimerized version of OKT3, Leu 4, 500A2, CLB T3/3, M291, YTH 12.5, or BMA030.

12. The use of claim 11, wherein said antibody is humanized OKT3γ1 ala ala.

13. The use of claim 8, wherein said autoimmune disorder is Type 1 diabetes, psoriasis, rheumatoid arthritis, lupus, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, multiple sclerosis, effects from organ transplantation, or graft vs. host disease (GVHD).

14. The use of claim 13, wherein said autoimmune disorder is Type 1 diabetes.

15. The use of any one of claims 8-10, wherein said antibody is to be administered at doses that escalate over the first three days of said dosage regimen until the maximum daily prophylactically or therapeutically effective amount of said antibody is achieved.

16. The use of any one of claims 8-10, wherein said antibody is to be administered at doses that escalate over the first four days of said dosage regimen until the maximum daily prophylactically or therapeutically effective amount of said antibody is achieved.

17. The use of any one of claims 8-10, wherein said antibody is to be administered at doses that escalate over the first half of the dosage regimen until the maximum daily prophylactically or therapeutically effective amount of said antibody is achieved.

18. The use of any one of claims 8-10, wherein said antibody is to be administered at doses that escalate by a factor of 2 until the daily prophylactically or therapeutically effective amount of said antibody is achieved.

19. The use of any one of claims 8-10, wherein said dosage regimen is no more than 5 days.

20. The use of any one of claims 8-10, wherein said dosage regimen is no more than 6 days.

21. The use of any one of claims 8-10, wherein said dosage regimen is no more than 7 days.

22. The use of any one of claims 8-10, wherein said dosage regimen is no more than 8 days.

23. The use of any one of claims 8-10, wherein said dosage regimen is no more than 9 days.

24. The use of any one of claims 8-10, wherein said dosage regimen is no more than 10 days.

CLAIMS:

1. Use of an anti-CD3 antibody that comprises an Fc domain having an amino acid modification, wherein said modified Fc domain does not bind any FcγR; in the manufacture of a medicament for treating an autoimmune disorder or ameliorating the symptoms thereof in a patient in need thereof,

wherein said antibody is OKT3, Leu-4, 500A2, CLB-T3/3, M291, YTH 12.5 or BMA030;

wherein said medicament is to be administered to said patient in a dosage regimen comprising administration of increasing amounts of said antibody on at least the initial 4 days of said dosage regimen until a maximum daily prophylactically or therapeutically effective amount of said antibody is achieved;

wherein said maximum daily prophylactically or therapeutically effective amount is 35 μg/kg or less of said antibody and;

wherein said autoimmune disorder is selected from Type 1 diabetes, psoriasis, and rheumatoid arthritis.

2. The use of claim 1, wherein said maximum daily prophylactically or therapeutically effective amount is 30 μg/kg or less of said antibody.

3. The use of any preceding claim, wherein said maximum daily prophylactically or therapeutically effective amount is 25 μg/kg or less of said antibody.

4. The use of any preceding claim, wherein said maximum daily prophylactically or therapeutically effective amount is 20 μg/kg or less of said antibody.

5. The use of any preceding claim, wherein said maximum daily therapeutically effective amount is 15 μg/kg or less of said antibody.

6. The use of any preceding claim, wherein said maximum daily therapeutically effective amount is 10 μg/kg or less of said antibody.

7. The use of any preceding claim, wherein said antibody is humanized OKT3γ1 ala-ala.

8. The use of any preceding claim, wherein said antibody is to be administered at doses that escalate over the first half of the dosage regimen until the maximum daily prophylactically or therapeutically effective amount of said antibody is achieved.

9. The use of any preceding claim, wherein said antibody is to be administered at doses that escalate by a factor of 2 until the maximum daily prophylactically or therapeutically effective amount of said antibody is achieved.

10. The use of any preceding claim, wherein said dosage regimen is no more than 4 days.

11. The use of any preceding claim, wherein said dosage regimen is no more than 5 days.

12. The use of any preceding claim, wherein said dosage regimen is no more than 6 days.

13. The use of any preceding claim, wherein said dosage regimen is no more than 7 days.

14. The use of any preceding claim, wherein said dosage regimen is no more than 8 days.

15. The use of any preceding claim, wherein said dosage regimen is no more than 9 days.

16. The use of any preceding claim, wherein said dosage regimen is no more than 10 days.

17. The use of any preceding claim, wherein said dosage regimen is no more than 11 days.

18. The use of any preceding claim, wherein said dosage regimen is no more than 12 days.

19. The use of any preceding claim, wherein said dosage regimen is no more than 13 days.

20. The use of any preceding claim, wherein said dosage regimen is no more than 14 days.

21. The use of any preceding claim, wherein the dose on day 1 is approximately 1.6 μg/kg, the dose on day 2 is approximately 3.2 μg/kg, the dose on day 3 is approximately 6.5 μg/kg, the dose on day 4 is approximately 13 μg/kg, and the dose on subsequent days is approximately 26 μg/kg.

22. The use of claim 21, wherein said dosage regimen is 5 days or less.

23. The use of claim 21, wherein said dosage regimen is 6 days or less.

24. The use of claim 21, wherein said dosage regimen is 7 days or less.

25. The use of claim 21, wherein said dosage regimen is 8 days or less.

26. The use of claim 21, wherein said dosage regimen is 9 days or less.

27. The use of claim 21, wherein said dosage regimen is 10 days or less.

28. The use of claim 21, wherein said dosage regimen is 11 days or less.

29. The use of claim 21, wherein said dosage regimen is 12 days or less.

30. The use of claim 21, wherein said dosage regimen is 13 days or less.

31. The use of claim 21, wherein said dosage regimen is 14 days or less.

32. The use of any preceding claim, wherein on at least the first day of said dosage regimen, said antibody is to be administered in roughly equal portions at intervals of at least 6 hours, at intervals of at least 8 hours, or at intervals of at least 12 hours.

33. The use of any preceding claim, wherein on at least the first day of said dosage regimen, said antibody is to be administered in increasing portions at intervals of at least 6 hours, at intervals of at least 8 hours, or at intervals of at least 12 hours.

34. The use of any preceding claim, wherein said medicament is formulated for administration by a route selected from the group consisting of intravenous, intramuscular, subcutaneous or oral.

35. The use of claim 34, wherein said medicament is formulated for administration by an intravenous route over a period of at least 30 minutes.

36. The use of any preceding claim, wherein said medicament is formulated for administration in combination with an immunosuppressant.

37. The use of any preceding claim, wherein said autoimmune disorder is Type 1 diabetes.

38. The use of claim 37, wherein, prior to said treatment, the HA1c of said patient is less than 7.5% or the C-peptide response of said patient to a mixed-meal tolerance test (MMTT) results in a mean area under the curve for the initial 4 hours of at least 100 pmol/ml.

39. The use of claim 37 or 38 wherein said medicament is formulated for administration in combination with administration of insulin, exenatide, or pramlinitide.

40. The use of any of claims 37-39, wherein said patient is in the early stages of Type 1 diabetes when less than about 80% of β-cells have been destroyed.

41. The use of any of claims 37-40, wherein said patient is a child.

42. The use of any of claims 1-36, wherein said autoimmune disorder is rheumatoid arthritis.

43. The use of claim 42, wherein said patient is in the early stages of rheumatoid arthritis when autoreactive cytotoxic T-lymphocytes are detected in synovial tissues but clinical symptoms of rheumatoid arthritis have not yet developed.

44. The use of any of claims 1-36, wherein said autoimmune disorder is psoriasis.